Back to top
more

Tandem Diabetes Care (TNDM)

(Delayed Data from NSDQ)

$33.11 USD

33.11
1,040,983

+0.26 (0.79%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $33.13 +0.02 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Instruments

Zacks News

Delcath Systems, Inc. (DCTH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Delcath Systems (DCTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Tandem Diabetes Care, Inc. (TNDM) to Report a Decline in Earnings: What to Look Out for

Tandem Diabetes Care (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Down -21.69% in 4 Weeks, Here's Why Tandem Diabetes Care (TNDM) Looks Ripe for a Turnaround

Tandem Diabetes Care (TNDM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

t:slim X2's Compatibility With Lilly's Lyumjev Might Aid TNDM Stock

By integrating ultra-rapid acting insulin such as Lyumjev, which responds faster than traditional insulin, Tandem Diabetes Care is enhancing the pump's functionality.

TNDM Stock Likely to Gain From Innovation Amid Competition

Tandem Diabetes is driving transformative innovation to help reduce the burden of diabetes and create new possibilities for people living with the condition.

TNDM Stock Likely to Benefit From the t:slim X2-Lyumjev Offering in EU

Tandem Diabetes' t:slim X2 insulin pump is now compatible with Lilly's Lyumjev in the European Union.

Reasons to Hold Tandem Diabetes Stock in Your Portfolio Now

Innovations and a robust diabetes market outlook raise investors' optimism for TNDM.

New Launches Support Tandem Diabetes Stock Despite Macro Concerns

The latest addition to TNDM's pump platform portfolio, Tandem Mobi, is leading the way in creating a whole new category of devices for insulin therapy.

Medtronic (MDT) Progresses in CGM With New Approval, Alliance

The FDA approval for Medtronic's (MDT) Simplera CGM sets the stage for further regulatory submissions of the updated InPen smart insulin pen app.

Tandem Diabetes (TNDM) Q2 Earnings Beat, '24 View Raised

Tandem Diabetes' (TNDM) top and bottom lines outpace estimates in the second quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.

Tandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Tandem Diabetes Care (TNDM) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Tops Revenue Estimates

Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of 12.96% and 7.50%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Inari Medical, Inc. (NARI) Reports Q2 Loss, Tops Revenue Estimates

Inari Medical (NARI) delivered earnings and revenue surprises of -156.25% and 1.30%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Here's How Thermo Fisher (TMO) is Placed Ahead of Q2 Earnings

Strength in Analytical Instrument and Laboratory Products and Services segments is likely to have driven Thermo Fisher's (TMO) second-quarter 2024 performance.

Will WATCHMAN Sales Aid Boston Scientific's (BSX) Q2 Earnings?

In EMEA, Boston Scientific (BSX) is expected to have registered growth within structural heart, including Transcatheter aortic valve replacement, WATCHMAN and other interventional cardiology therapies.

Is a Beat Likely for Edwards Lifesciences (EW) in Q2 Earnings?

Edwards Lifesciences' (EW) TMTT segment's PASCAL platform is likely to have maintained strong growth momentum in the second quarter globally, backed by its portfolio of differentiated therapies.

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

Smart Beta ETF report for XHE

Tandem Diabetes (TNDM) Posts Positive Data for Tandem Mobi

Tandem Diabetes (TNDM) unveils survey results of the new Tandem Mobi insulin delivery system, underscoring its potential to significantly enhance the quality of life for people with diabetes

Why Is OPKO Health (OPK) Up 12.8% Since Last Earnings Report?

OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Hold on to Tandem Diabetes (TNDM) Now

Innovations and a robust diabetes market outlook raise investors' optimism for Tandem Diabetes (TNDM).

Tandem Diabetes (TNDM) Connects Mobi Pump With Dexcom G7 Sensor

Tandem Diabetes' (TNDM) Mobi insulin pump is now compatible with Dexcom G7 CGM.

Tandem Diabetes (TNDM) Hits 52-Week High: What's Driving It?

Tandem Diabetes (TNDM) outperforms the industry, owing to its impressive series of product launches and an impressive quarterly performance.

Tandem Diabetes (TNDM) Posts Narrower Q1 Loss, Raises '24 View

Tandem Diabetes (TNDM) outperforms in the first quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.

Tandem Diabetes Care (TNDM) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Tandem Diabetes Care (TNDM) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Tops Revenue Estimates

Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of 21.25% and 10.76%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?